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a b s t r a c t 
The COVID-19 outbreak is spreading worldwide pushing the 
national healthcare systems to find effective protocols to pre- 
vent contagion and to reduce the patients’ mortality and 
the severity of long-term effects. In the absence of autho- 
rised pharmacological treatments, chloroquine, and hydrox- 
ychloroquine, which are known as anti-malaria drugs, had 
been widely used off-label until concerns about their effi- 
cacy/safety limited their use to hospitalized patients affected 
by severe COVID-19. Regardless of their clinical use, their 
manipulation is necessary since the pure drug substance is 
not always promptly available and most of the drug products 
available on the market are tablets designed to be ingested; 
no liquid dosage forms are available. These are needed for 
children and the enteral nutrition of inpatients of intensive 
care units. Considering that both chloroquine and hydrox- 
ychloroquine are BCS class I, proper procedures for purify- 
ing the preparation from the insoluble excipients may be 
adopted to avoid clogging of a nasogastric tube and to re- 
duce the drug content variability in the administered doses. 
The data in this article indicate that compounded oral sus- 
pensions containing chloroquine and hydroxychloroquine can 
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be filtered and/or centrifuged without altering the drug assay 
of the preparation. 
© 2020 The Author(s). Published by Elsevier Inc. 
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t  Specifications Table 
Subject Pharmacology, Toxicology and Pharmaceutical Science 
Specific subject area Pharmaceutical Science 
Type of data Table, Text 
How data were acquired High-pressure liquid chromatography (HPLC) 
Data format Raw and analysed 
Parameters for data collection Data on the drug assay of the compounded oral suspensions containing 
chloroquine and hydroxychloroquine before and after filtration and 
centrifugation 
Description of data collection The drug suspensions were prepared by manipulating chloroquine and 
hydroxychloroquine tablets. The impact of filtering and centrifuging was tested 
on three-vehicle suspensions. The samples were analysed by HPLC. 
Data source location Milan, Italy 
Data accessibility Data with the article. Raw data and chromatograms with supplementary 
materials 
alue of the data 
• The data provide evidence on the impact of filtration or centrifugation on the assay of chloro-
quine and hydroxychloroquine suspension obtained by industrial tablet trituration followed
by dispersion of the powder in different aqueous vehicles. 
• The data can be useful for healthcare professionals to compound oral solution/suspension
of highly water-soluble drug substance when an authorized solid dosage form is used as
drug source or the commercial-available drug product has to be manipulated to meet clinical
needs. 
• The data are insights for further studies focused on the development of new dosage forms
indicated for an inpatient with a nasogastric tube or paediatric patients 
. Data description 
Ad hoc pharmaceutical dosage forms suitable for paediatric patients or non-cooperative pa-
ients with a nasogastric tube used for the administration of nutrients are often absent. This
omplicates the management of the therapy pushing the pharmacist to prepare a suitable drug
roduct starting from the raw material or manipulating, after a risk assessment evaluation, other
ndustrially-produced solid dosage forms such as tablet, capsules, pellets and granules [1] . In this
ase, the dosage form must be triturated, e.g. in a mortar, and the obtained powder dispersed
n an appropriate vehicle. The final preparation can be a solution, if all components are soluble,
r a suspension. In this second case, three different scenarios are possible: a) both drug and
xcipients are not enough soluble and remain suspended in the vehicle b) the drug is not solu-
le in the vehicle and remains suspended, whereas the excipients are solubilized; c) the drug is
oluble, but the excipients do not remain suspended in the vehicle. For scenarios a) and b), the
ctivities of the compounding pharmacist should include an in-depth assessment of the physico-
hemical properties of both drug substance and excipients to select the most suitable vehicle for
uaranteeing the physicochemical stability of the suspension and its re-suspendability over the
ime [2] . In the scenario c), the adoption of proper procedures for purifying the preparation from
he insoluble excipients could be considered to avoid risks related to the clogging of the naso-
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Table 1 
Data on the assay of chloroquine extemporaneous suspensions after filtration. The extemporaneous suspensions were 
obtained dispersing the crushed tablets in different aqueous vehicles (i.e., purified water, CMC, FOSP). An aqueous solu- 
tion made of the pure drug substance was used as a control. The data are expressed as a mean percentage and relative 
standard deviation (RSD%) of three batches of suspension. 
Vehicle Filter Drug assay (%) RSD (%) 
4 mg/ml 25 mg/ml 4 mg/ml 25 mg/ml 
Control – 101.1 100.7 1.8 10.9 
0.2 μm, NYL 104.2 102.1 4.6 1.5 
0.2 μm, PES 101.4 99.6 1.7 1.3 
0.45 μm, PP 101.2 100.2 1.0 0.9 
0.45 μm, PTFE 101.5 99.7 3.1 0.9 
Water – 101.3 106.9 2.4 10.0 
0.2 μm, NYL 99.9 101.2 1.5 3.4 
0.2 μm, PES 100.4 102.1 2.1 3.4 
0.45 μm, PP 100.0 100.9 0.6 2.5 
0.45 μm, PTFE 100.0 99.3 0.7 0.3 
CMC – 108.0 114.0 7.3 6.4 
0.2 μm, NYL 102.4 103.7 0.9 1.0 
0.2 μm, PES 104.3 100.4 1.7 2.5 
0.45 μm, PP 104.4 105.5 1.7 3.7 
0.45 μm, PTFE 103.4 102.6 1.6 3.9 
FOSP – 97.7 103.7 2.1 7.1 
0.2 μm, NYL 105.4 103.3 2.4 5.8 
0.2 μm, PES 100.4 97.9 2.9 2.7 
0.45 μm, PP 99.7 99.0 3.9 2.2 
0.45 μm, PTFE 99.4 102.3 2.7 3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 gastric tube and consequently heterogenicity of the drug dose. However, filtration may affect the
drug concentration due to retention of the drug by the filter if the compatibility between drug
and filter membrane has not been previously verified. In the last months, chloroquine and hy-
droxychloroquine, which are authorised for malaria and certain autoimmune diseases, have been
extensively used for the management of COVID-19. However, since concerns about efficacy/safety
of antimalarials have been reported in the literature [3] , the use of hydroxychloroquine has been
advised against, limiting the use in hospitalized patients affected by severe COVID-19 [4] . 
In the absence of industrially-produced liquid dosage forms, the commercial tablets have
been ground to allow the administration to non-cooperative patients. Both drugs are classified
in BCS Class I (i.e. water-soluble and well-absorbed). Thus, they appear as an interesting case to
evaluate the advantages/disadvantages of clarification after aqueous dispersion of the triturated
tablets. 
Herein, the impact of filtration and centrifugation on the drug assay of oral chloro-
quine/hydroxychloroquine suspensions obtained by tablet manipulation is presented. The impact
of filtration was investigated on filters which are like those commonly used in the compounding
laboratories and as in-line filters for volumetric pump devices by using suspensions of different
concentrations and aqueous vehicles. The centrifugation was applied as a method for purifying
the preparation from insoluble excipients only if difficulties in filtering were observed during
the experiments. The physicochemical stability of the suspensions overtime was not investigated
since the existing literature suggested that both drugs are stable in aqueous systems for months
[5] . 
Tables 1 and 2 reported the data on assays of both chloroquine and hydroxychloroquine be-
fore and after filtration with syringe filters made with a different pore size (i.e., 0.2, 0.45 μm) and
membrane material. Data were obtained by using membranes made of nylon (NYL), polyether-
sulfone (PES), polypropylene (PP), polytetrafluoroethylene (PTFE). 
The data show that none of the tested filters affects the assay of both drugs, which remain
within the ±10% range of the declared one as prescribed by both USP and Ph. Eur. [ 6 , 7 ]. No
significant differences are observable among the different vehicles or in comparison to the con-
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Table 2 
Data on the assay of hydroxychloroquine extemporaneous suspensions after filtration. The extemporaneous suspensions 
were obtained dispersing the crushed tablets in different aqueous vehicles (i.e., purified water, CMC, FOSP). Drug solution 
in water was used as a control. The data are expressed as a mean percentage and relative standard deviation (RSD%) of 
three batches of suspension. 
Vehicle Filter Drug assay (%) RSD (%) 
4 mg/ml 25 mg/ml 4 mg/ml 25 mg/ml 
Control – 99.6 99.4 3.2 3.5 
0.2 μm, NYL 102.5 98.6 2.8 1.8 
0.2 μm, PES 104.0 97.0 3.2 2.9 
0.45 μm, PP 101.5 98.8 1.3 2.5 
0.45 μm, PTFE 106.1 97.9 2.2 5.1 
Water – 104.8 112.2 3.0 14.3 
0.2 μm, NYL 101.4 98.1 2.4 5.4 
0.2 μm, PES 102.1 99.4 3.7 2.7 
0.45 μm, PP 101.3 98.6 2.9 7.2 
0.45 μm, PTFE 101.1 95.4 2.8 7.2 
CMC – 100.5 100.5 7.4 13.9 
0.2 μm, NYL 104.2 101.4 1.2 9.4 
0.2 μm, PES 103.2 102.3 1.4 5.0 
0.45 μm, PP 101.4 99.1 3.5 8.1 
0.45 μm, PTFE 101.5 98.2 2.7 5.2 
FOSP – 99.9 96.4 0.5 4.2 
0.2 μm, NYL 97.8 94.3 2.9 6.6 
0.2 μm, PES 102.5 96.1 2.0 5.7 
0.45 μm, PP 99.5 96.7 3.6 1.2 
0.45 μm, PTFE 96.6 103.2 5.8 8.9 
Table 3 
Data on the assay of chloroquine, and hydroxychloroquine extemporaneous suspensions (25 mg/ml) after weak centrifu- 
gation (30 0 0 rpm, 25 °C, 5 min). The extemporaneous suspensions were obtained dispersing the crushed tablets in differ- 
ent aqueous vehicles (i.e., purified water, CMC, FOSP). The data are expressed as a mean percentage and relative standard 
deviation (RSD%) of three batches of suspension. 
Vehicle Drug assay (%) RSD (%) 
Chloroquine Hydroxychloroquine Chloroquine Hydroxychloroquine 
Water 101.8 102.8 5.0 3.3 
CMC 102.0 98.6 3.2 5.3 
FOSP 103.6 98.7 3.9 3.8 
t  
v  
fi  
M  
s
 
c  
s  
p  
t  
frol solution. However, it is noteworthy that the most significant deviations and inter-sample
ariability from the expected assay were observable for no filtered suspensions, suggesting that
ltration may improve the reproducibility of the preparation dosing at the patient’s bedside.
oreover, the experimental data seemed to suggest good compatibility between the drug sub-
tances and the membrane filters. 
However, the experimental evidence suggested that 25 mg/ml suspensions were more diffi-
ult in filtering than 4 mg/ml ones with a higher risk of filter clogging. For high-concentration
uspensions, centrifugation can be an alternative method for eliminating the inactive suspended
articulates. Table 3 reported the data on assays of both chloroquine and hydroxychloroquine af-
er weak centrifugation. As reported, the drug assay in the supernatant was within specification
or both drugs, regardless of the vehicle viscosity. 
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 2. Experimental design, materials, and methods 
2.1. Materials 
Clorochina Bayer (Bayer AG, I). 250 mg chloroquine bisphosphate. Excipients: corn starch, talc,
magnesium stearate, hypromellose, macrogol 400, titanium dioxide [8] . 
Plaquenil (Sanofi S.p.A., I). 200 mg hydroxychloroquine sulphate. Excipients: lactose monohy-
drate, povidone, corn starch, magnesium stearate, Opadry OY- L -28900 (hypromellose, macrogol
400, titanium dioxide, lactose monohydrate) [8] . 
Syringe filters with 0.2 μm nylon (NYL) membrane, 0.2 μm polyethersulfone (PES) membrane,
0.45 μm polypropylene (PP) membrane, and 0.45 μm polytetrafluoroethylene (PTFE) membrane
were purchased by VWR International (I). Sodium carboxymethyl cellulose (CMC), trisodium cit-
rate dihydrate, citric acid, and Fast Oral Solution Puccini (FOSP) were purchased by Farmalabor
(I). All other chemicals/solvents used in the study were analytical grade and used without fur-
ther purification. 
2.2. Suspension preparation 
A known number of tablets containing chloroquine or hydroxychloroquine were crushed in
a mortar to obtain a fine and homogenous powder. The crushing procedures were carried out
under hood by operators suitably equipped with proper personal protective equipment to avoid
health risks associated with drug exposure. Then, the powder was precisely weighed to obtain
suspension of 4 and 25 mg/ml when dispersed in 50 ml of one of the three vehicles selected,
namely: purified water, 1% w/v CMC solution in pH 4.2 citrate buffer and FOSP. The preparations
were mechanically mixed for 10 min at least to reach a homogenous whitish suspension. The
obtained suspension was then stored in well-closed and light-resistant containers until use. The
data resulted from the preparation of three suspension batches for each concentration. 
2.3. Purification of the preparation 
The drug-loaded suspensions obtained using both drug substance and manipulated tablets
were purified by filtration and/or centrifugation to eliminate the precipitated insoluble materials.
2.3.1. Filtration 
Aliquots of the 4 and 25 mg/ml suspensions and control solutions were filtered by using four
syringe filters, which differed by the membrane material and pore size (0.2, 0.45 μm). The fil-
trates were diluted with purified water (1:4 v/v for 4 mg/ml; 1:25 v/v for 25 mg/ml), mixed by
vortex and then analysed in HPLC. 
2.3.2. Centrifugation 
Aliquots of the 25 mg/ml suspensions were centrifuged at 30 0 0 rpm, 25 °C for 5 min. The su-
pernatant was then diluted with purified water (1:4 v/v for 4 mg/ml; 1:25 v/v for 25 mg/ml),
mixed by vortex and then analysed in HPLC. 
2.4. HPLC method 
2.4.1. Chloroquine 
The drug quantification was performed using the analytical method described by Coelho and
co-workers [9] . Briefly, an Agilent 1100 HPLC system equipped with an autosampler, a quater-
nary pump with degasser, a thermostated column compartment set at 40 °C, and a diode array
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Table 4 
Chromatographic condition of hydroxychloroquine (Gradient). 
Time (min) Solvent A% Solvent B% 
0 90 10 
2 90 10 
5 80 20 
5.1 90 10 
10 90 10 
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 etector set at 250 nm (Agilent, US). A reverse-phase column C18 was used as the stationary
hase (InertClone ODS (3), 250 ×4,6 mm, 5 μm, Phenomenex, US). A combination of methanol
nd phosphate buffer at pH 3 (0.01 M) plus 0.5%b w/v of triethanolamine (75:25) was used as
he mobile phase. The flow rate was set at 1.0 mL/min. The injection volume was 10 μL. The
rug concentration was determined from three standard calibration curves in the range of 0.1–
.6 mg/ml. Chromatograms and analyses’ raw data are reported in Supplementary materials. 
.4.2. Hydroxychloroquine 
The HPLC method used was derived for a method recently published by USP [10] . The drug
uantification in suspensions was determined using an Agilent 1100 HPLC system equipped with
 diode array detector at 254 nm (Agilent, US). A reverse-phase column was used as the station-
ry phase (InertClone ODS (3) C18, 5 μm, 4.6 ×150 mm, Phenomenex, US). The analyses were
erformed in gradient conditions by using a combination of acetonitrile and HPLC-water plus
 3 PO 4 (1:400) at pH 3 as the mobile phase ( Table 4 ). The flow rate was set at 1.0 mL/min. The
njection volume was 5 μL, and the column temperature fixed at 40 °C. The drug concentration
as determined from three standard calibration curves in the range of 0.1–1.25 mg/ml. Chro-
atograms and analyses’ raw data are reported in Supplementary materials. 
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